In a South African psychiatric hospital, a two-year study of 370 patients revealed that nearly half were active cannabis users — a finding that places an old clinical suspicion on firmer empirical ground. The research, published in the South African Journal of Psychiatry, documents how the convergence of cannabis use and psychotic illness creates a harder, more relentless form of suffering: earlier onset, greater severity, poorer adherence to treatment, and cascading losses in housing, employment, and family stability. This is not a story of moral failing but of compounding vulnerability — you
South African study links cannabis use to severe psychosis, higher relapse rates
Individuals with comorbid cannabis use and psychosis face homelessness, violence, incarceration, and relationship/employment disruption; families bear increased caregiving burden.
Cannabis users with psychosis face earlier onset, more severe symptoms, and higher relapse rates
Mark
Why does cannabis use seem so prevalent among people already experiencing psychosis? Is it the illness driving the use, or the use driving the illness?
Mimi
The researchers found it's likely both. Some people use cannabis to cope with the distressing symptoms of early psychosis—it's a form of self-medication. But cannabis can also trigger or worsen psychotic symptoms in people who are vulnerable. The relationship isn't simple causation; it's more like a feedback loop.
Mark
The study mentions high-potency cannabis as a particular concern. How much has the product itself changed?
Mimi
That's the shift nobody talks about enough. The cannabis available now is far more concentrated than it was even a decade ago. The research suggests high-potency products carry a substantially higher risk of triggering first-episode psychosis. In South Africa, where cannabis was decriminalized before this study, the availability and potency may have changed the patterns of use significantly.
Mark
What happens to someone who has both conditions and stops taking their psychiatric medication?
Mimi
The study found that cannabis users with psychosis struggle more with medication adherence. When they stop taking antipsychotics, relapse becomes more likely, symptoms intensify, and the cycle of hospitalization repeats. Some end up homeless or incarcerated. It's not just the individual suffering—families become exhausted from the burden of care.
Mark
The demographic profile is striking—mostly young, unemployed, poorly educated. Does the study suggest cannabis use causes that, or reflects it?
Mimi
The study doesn't claim causation there. What it shows is that young, unemployed people with psychotic disorders are the ones most likely to use cannabis. Whether poverty and unemployment make cannabis use more likely, or whether the dual diagnosis makes employment impossible, the study doesn't untangle. But the vulnerability is clear.
Mark
If cannabis was decriminalized in South Africa, does that mean public health messaging about this risk has changed?
Mimi
That's the open question the researchers raise. Decriminalization is one thing; public health guidance about cannabis use among people with psychotic disorders is another. The researchers note that cultural and environmental factors in South Africa may differ from other countries, and the post-decriminalization landscape may require different interventions.
Der Puls
- Nearly half of hospitalized psychotic patients in South Africa were actively using cannabis at admission, a rate that clinicians suspected but had rarely seen quantified so precisely.
- Cannabis use correlates with earlier symptom onset, more intense psychotic episodes, and a persistent failure to take prescribed medications — each factor feeding the next in a cycle difficult to interrupt.
- The consequences extend far beyond the clinic: patients face homelessness, violence, incarceration, and the collapse of employment and relationships, while families absorb caregiving burdens that compound with each relapse.
- The causal arrow runs in both directions — cannabis can trigger psychosis in vulnerable individuals, but people in early psychosis also reach for cannabis to quiet distressing symptoms, making intervention complex.
- South Africa's decriminalization of personal cannabis use and the global rise of high-potency products have raised the stakes, prompting researchers to call for targeted public health responses before patterns harden further.
In a South African psychiatric hospital, a two-year study of 370 patients revealed that nearly half were active cannabis users — a finding that places an old clinical suspicion on firmer empirical ground. The research, published in the South African Journal of Psychiatry, documents how the convergence of cannabis use and psychotic illness creates a harder, more relentless form of suffering: earlier onset, greater severity, poorer adherence to treatment, and cascading losses in housing, employment, and family stability. This is not a story of moral failing but of compounding vulnerability — young, largely unemployed men cycling through hospitalizations in a country where cannabis use among people with psychosis has long been common, and where recent decriminalization may yet reshape the landscape further. The study asks a question that public health cannot afford to defer: when the most vulnerable are also the most exposed, what does care actually require?
A two-year review of 370 admissions at a South African psychiatric hospital found that nearly half the patients were active cannabis users — a figure that crystallizes what clinicians have long observed but rarely measured with such precision. Published in the South African Journal of Psychiatry, the study documents a clear and troubling pattern: cannabis use among people with schizophrenia and other psychotic disorders is associated with earlier illness onset, more severe symptoms, and a persistent struggle to maintain prescribed medication regimens. The downstream effects accumulate — higher relapse rates, longer hospitalizations, and for many, a slide into homelessness, violence, or incarceration.
The patients themselves reflect a particular kind of vulnerability. Roughly two-thirds were between 16 and 34 years old, seventy percent were male, nearly ninety percent were unemployed, and most had not progressed beyond primary school. Many had been hospitalized three or more times, cycling through admissions while trying to hold onto some semblance of stability — often with cannabis use woven into that struggle. Families bearing the weight of care found themselves managing not one condition but two, with each complicating the other.
The researchers were careful not to reduce the relationship to simple causation. Cannabis can precipitate psychotic symptoms in those who are genetically or environmentally vulnerable, but people already experiencing early psychosis may also turn to cannabis in search of relief — a two-way dynamic that makes clinical intervention genuinely difficult. What has sharpened the concern in recent years is the rising potency of cannabis products, which research increasingly links to elevated risk for first-episode psychosis and schizophrenia.
South Africa's context adds further complexity. Historical studies have found cannabis use among psychotic patients at rates ranging from 35% to nearly 69%, depending on the region and population. The country's decriminalization of personal cannabis use — which preceded this study — may have altered those patterns in ways not yet fully visible. The researchers frame their findings not as moral verdict but as clinical prognosis: for a person navigating psychosis, cannabis use measurably worsens the odds. In a country where this combination is common and the legal landscape is shifting, that prognosis carries urgent implications for both public health planning and everyday care.
A psychiatric hospital in South Africa admitted 370 patients over two years, and when researchers examined their records, they found something striking: nearly half were using cannabis. The study, published in the South African Journal of Psychiatry, documents what clinicians have long suspected but rarely quantified with such clarity—that cannabis use among people living with schizophrenia and other psychotic disorders correlates with a measurably harder illness to treat and manage.
The numbers tell a particular story. Among the patients studied, 48.9% were active cannabis users at the time of admission, while another 51.1% had used cannabis at some point in their lives. The researchers found that those who used cannabis tended to develop psychotic symptoms earlier in life, experienced more intense symptoms, and struggled more consistently with taking psychiatric medications as prescribed. The consequences rippled outward: higher rates of relapse, longer hospital stays, poorer functional outcomes. For some, the deterioration extended into homelessness, violence, and incarceration. Families bearing the weight of care found themselves managing not one illness but two, with compounding strain.
The study population itself reflected vulnerability. About two-thirds of the patients were between 16 and 34 years old. Seventy percent were male. Nearly 90% were unemployed, and 88% had not progressed beyond primary school education. The median duration of psychotic illness was three years, and nearly half had been hospitalized three or more times. These were not first-episode patients; many had lived with psychosis for years, cycling through admissions, struggling with medication adherence, trying to maintain some foothold in employment or relationships while managing a severe mental illness—and often, cannabis use alongside it.
The relationship between cannabis and psychosis, however, is not straightforward causation in one direction. The researchers acknowledged a two-way street: cannabis use can precipitate psychotic symptoms in vulnerable individuals, but people experiencing early psychotic symptoms may also self-medicate with cannabis, seeking relief from distressing experiences. Genetic and environmental factors likely shape who becomes vulnerable to this dual diagnosis. What has changed in recent years is the potency of the cannabis itself. Recent research suggests that high-potency cannabis carries a substantially elevated risk for first-episode psychosis and subsequent schizophrenia—a concern that has grown as cannabis products have become more concentrated.
South Africa's particular context matters here. The country has historically reported cannabis use among people with psychotic disorders at rates ranging from 35% to 68%, depending on the population studied and the region. One study in KwaZulu-Natal found cannabis use in nearly 69% of adolescents with psychotic disorders. These figures predate the decriminalization of personal cannabis use in South Africa, which occurred before this study was conducted. The researchers note that the landscape may have shifted since earlier studies were completed roughly a decade ago. Cultural factors, environmental conditions, the availability of cannabis, and changes in legislation all influence patterns of use in ways that may differ substantially from other countries.
What the study underscores is the clinical reality: a person with schizophrenia or another psychotic disorder who also uses cannabis faces a steeper climb. They are more likely to stop taking medication, more likely to relapse, more likely to lose employment and housing, more likely to experience violence or legal consequences. Their families carry a heavier burden. The researchers frame this not as moral judgment but as a prognostic fact—the dual diagnosis of cannabis use and psychotic disorder is, by the measures that matter clinically, a poor prognostic indicator. In a country where cannabis use among people with psychotic illness has been common and where the legal landscape has shifted, understanding this relationship becomes urgent for public health planning and clinical practice.
Bemerkenswerte Zitate
Cannabis users with psychosis have earlier onset of illness, increased symptom severity, poorer adherence to psychiatric medication, poorer functional outcomes, higher relapse rates and longer hospital stays compared with non-users.— South African Journal of Psychiatry study researchers
People with schizophrenia spectrum and other psychotic disorders and comorbid cannabis use tend to have poorer psychosocial functioning, homelessness, violence, incarceration and increased burden of care for families.— Study researchers
Möchten Sie die ganze Geschichte?
Das Original lesen bei IOL ↗
Science & Space